

AD _____

Award Number: DAMD17-00-1-0489

TITLE: A Potential Therapeutic Role of J Series Prostaglandins
in PPARY Mediated Treatment of Breast Cancer

PRINCIPAL INVESTIGATOR: Arta M. Monjazez

CONTRACTING ORGANIZATION: Wake Forest University School of
Medicine
Winston-Salem, North Carolina 27157

REPORT DATE: June 2002

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

20030211 218

REPORT DOCUMENTATION PAGE

Form Approved
OMB No. 074-0188

Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302, and to the Office of Management and Budget, Paperwork Reduction Project (0704-0188), Washington, DC 20503

1. AGENCY USE ONLY (Leave blank)		2. REPORT DATE June 2002	3. REPORT TYPE AND DATES COVERED Annual Summary (15 May 01 - 14 May 02)	
4. TITLE AND SUBTITLE A Potential Therapeutic Role of J Series Prostaglandins in PPAR γ Mediated Treatment of Breast Cancer			5. FUNDING NUMBERS DAMD17-00-1-0489	
6. AUTHOR(S) Arta M. Monjazez				
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Wake Forest University School of Medicine Winston-Salem, North Carolina 27157 E-Mail: amonjaze@wfubmc.edu			8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012			10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES				
12a. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited			12b. DISTRIBUTION CODE	
13. ABSTRACT (Maximum 200 Words) No Abstract provided				
14. SUBJECT TERMS breast cancer			15. NUMBER OF PAGES 12	
			16. PRICE CODE	
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT Unlimited	

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18
298-102

Table of Contents

Cover	1
SF 298	2
Table of Contents	3
Introduction	4
Body	5
Key Research Accomplishments	7
Reportable Outcomes	7
Conclusions	10
References	11
Appendices	12

Introduction

The peroxisome proliferator activated receptor gamma (PPAR γ), is a potential therapeutic target for the treatment of breast cancer but the endogenous ligand for PPAR γ is not yet known. Recent data suggest that the endogenous ligand of PPAR γ may be a bioactive metabolite of arachidonic acid that is synthesized in normal breast tissue. Activation of PPAR γ with different agonists (e.g. 15deoxy Δ 12,14PGJ₂, troglitazone) elicits different physiological responses in breast cancer cells (i.e. differentiation or apoptosis) raising questions of the role PPAR γ plays in normal breast cell physiology. Results from our initial experiments show that prostaglandin metabolites of arachidonic acid inhibit cell cycle progression of MDA-MB-231 breast cancer cells. This cell cycle block induces apoptosis of breast cancer cells and inhibits tumor formation in nude mice. We hypothesize that human breast cancer cell lines (and human breast cancer tumors) have aberrant PPAR γ mediated signal transduction pathways or contain disrupted pathways for the metabolism of fatty acid derivatives that act as PPAR γ agonists. Understanding the metabolism of fatty acids in breast cancer cells, and elucidating the molecular and signal transduction events that are mediated by PPAR γ agonists may lead to novel strategies for the prevention and treatment of breast cancer.

Body


There is extensive literature on the use of retinoic acid and its derivatives, acting through their receptors (RAR and RXR), to arrest or reverse cancer in both animals and humans. Another member of the nuclear receptor superfamily, peroxisome proliferator activated receptor-gamma (PPAR γ), has an important role in fat metabolism and adipocyte differentiation. Although its natural ligand is not yet known, synthetic thiazolidinediones, certain fatty acids and metabolites of arachidonic acid, activate PPAR γ . Recent data reveal that PPAR γ is expressed in colonic tumors and metastatic breast adenocarcinomas, which raises the critical question of its functional significance in human cancers. RXR α and PPAR γ agonists together have been shown to induce apoptosis of estrogen receptor positive breast cancer cell lines *in vitro* and attenuate tumor growth in mice. Our studies show that prostaglandin agonists of PPAR γ alone inhibit cell cycle progression of both estrogen receptor positive and negative breast cancer cell lines via apoptosis and inhibit tumor formation in nude mice.

There are three specific aims for the pre-doctoral research hypothesis that human breast cancer cell lines (and human breast cancer tumors) have aberrant PPAR γ mediated signal transduction pathways or contain disrupted pathways for the metabolism of fatty acid derivatives that act as PPAR γ agonists.

- 1) The first aim is to determine the physiologic activities of different PPAR γ agonists on the proliferation of human breast cancer cell lines and primary human breast cancer cells. We will extend our published findings to include other natural prostanoid and eicosanoid agonists (e.g. PGE₂, DHA), synthetic PPAR γ agonists (e.g. BRL49653, ciglitazone) and co-activators that can potentiate the effects of PPAR γ agonists (e.g. 9-*cis*-retinoic acid, all-*trans*-retinoic acid).
- 2) The second aim is to determine the molecular mechanisms and signal transduction events that underlie PPAR γ mediated differentiation or apoptosis in breast cancer cells.
- 3) The third aim is to determine the metabolism of J-series prostaglandins in normal breast tissue and breast cancer cells.

Aim 1: Our studies of other natural and synthetic PPAR γ agonists show that several arachidonic acid (AA) metabolites, including 5- and 15-HETEs and 5- and 15-oxo-EETs, are activators of PPAR γ . However, of all the naturally occurring metabolites tested, the terminal derivative of prostaglandin D₂ metabolism, 15deoxy $\Delta^{12,14}$ PGJ₂ (15dPGJ₂), remains the most potent. A major accomplishment of Mr. Clay's was his observation that the published literature cites different physiologic outcomes in various cancer cell lines according to the concentration of PPAR γ agonist used. To this end, Mr. Clay authored a review article that documented the differing biological effects of PPAR γ activation in diverse cell types (1). Furthermore, Mr. Clay undertook the responsibility of determining if these diverse and opposing biologic outcomes occur in a single cell type (2). However mounting evidence in the literature and in Dr. Chilton's laboratory suggested that the induction of apoptosis might be independent to PPAR γ activation. After attending the PPARs Keystone Symposium in February 2000, Mr. Clay was successful in obtaining chemically synthesized selective agonists for each of the PPAR isoforms (α , GW7647; β/δ , GW0742 and γ , GW7845) from GlaxoSmithKlein (GSK) and a dominant negative PPAR γ construct (Figure 1). These compounds are

10,000 fold more selective for their respective receptor than for other nuclear receptors. Using a variety of techniques, Mr. Clay has shown that selective activation or inhibition of PPAR γ , using the synthetic agonist GW7845 or antagonist GW9662, does not alter cellular proliferation in breast cancer cell lines. Moreover, GW7845 does not induce apoptosis at any concentration tested (Figure 2) (3). Mr. Monjazebe, an MD/PhD candidate in his final year of his dissertation research in Dr. Chilton's laboratory has continued on the studies that Mr. Clay has




completed and will conclude the final year of this pre-doctoral research proposal. Mr. Monjazeab has shown that inhibition of arachidonic acid metabolism blocks cancer cell progression and results in cell death (4).

Aim 2: The molecular mechanisms and signal transduction events that underlie PPAR γ mediated differentiation or apoptosis in breast cancer cells are complex and not well understood. Mr. Clay has achieved great milestones in elucidating parts of these pathways. In a screen of 1,176 gene products by cDNA array analysis, Mr. Clay identified particular gene products that are increased in breast cancer cell lines after treatment with 15dPGJ₂ (5). Of these, the expression of the cyclin dependent kinase inhibitors p21^{Waf1/Cip1} (p21) and p27^{Kip1} (p27) and the cyclins D and E is increased >2 fold. Additionally, the expression of several genes involved in DNA maintenance and repair is decreased >2 fold. Mr. Clay has performed *post hoc* analysis of p21 and p27 expression by Western blot analysis to

confirm the results from the cDNA array. Additionally, Mr. Clay has followed up on published reports of the effects of 15dPGJ₂ in other cell systems to devise a potential mechanism by which 15dPGJ₂, or other cyclopentenone prostaglandins, may exert such potent anti-neoplastic activity in a variety of cancer cell types (Appendix 1). These studies resulted in a manuscript that was published in *The Journal of Biological Chemistry* (5). Mr. Mojazeab will continue this line of investigation to include other gene products and further elucidate the mechanisms described.

Aim 3: The studies of the metabolism of J-series prostaglandins in normal breast tissue and breast cancer cells are in the beginning stages. Mr. Clay was successful in obtaining a small amount of [³H]15dPGJ₂ through a collaborative effort with Dr. Kirk Maxey of Cayman Chemical. Using [³H]15dPGJ₂ to follow the metabolism of 15dPGJ₂ in the breast cancer cell line MDA-MB-231, Mr. Clay has noted that after 12 hours, the majority of label is still present as 15dPGJ₂. In this preliminary study, 66% of [³H]15dPGJ₂ was recovered after 12 hours. The remaining 44% was in the form of more polar metabolites as determined by thin layer chromatography (TLC). These derivative may represent a class of reactive oxygen species (ROS) that further activate PPAR γ (Appendix 1). Mr. Clay was unable to determine the structure of these polar metabolites, or their biological activity, due to the limited quantity of material, but Mr. Clay has enlisted the analytical expertise of the laboratory of Dr. Robert Murphy (National Jewish Research Center, Denver, Colorado) to assist with the determination of these structures by negative ion chemical ionization gas chromatography/tandem mass spectrometry (NICI GC/MS/MS). Moreover, Mr. Clay has obtained critical reagents for the study of prostaglandin metabolism. Specifically, Mr. Clay has acquired immuno-reactive antibodies to specific AA metabolizing enzymes. These include antibodies to fatty acid CoA ligase (FACL4), the enzyme that ligates free AA to Co-enzyme A, cyclooxygenase 2 (COX-2), the enzyme which catalyzes the oxidation and cyclization of AA to produce prostaglandin G₂ (PGG₂) and prostaglandin H₂ (PGH₂) and prostaglandin D₂ synthase (PGDS), the enzyme that catalyzes the formation of PGD₂ from PGG₂/PGH₂. These reagents will be helpful for the investigation of enzymatic levels of these critical metabolizing enzymes. In addition, enzymatic activity assay kits are readily available.

The research completed due to funding from this award has become a springboard for research currently being undertaken in other laboratories at Wake Forest University Baptist School of Medicine and was instrumental in allowing Mr. Clay to obtain a competitive post-doctoral fellowship at Washington University School of Medicine in St. Louis, Missouri. Mr. Monjazeab will make the most of the reagents that Mr. Clay has acquired and the collaborations that Mr. Clay has fostered to continue on the aims outlined in this proposal. Through collaboration with Dr. O'Flaherty (infectious diseases) and Dr. Robbins (radiation oncology) the mechanisms of oxidized lipid intermediates on PPARs on breast cancer cells will be continued to be explored (6,7).



Key Research Accomplishments

- 15deoxy $\Delta^{12,14}$ PGJ₂ remains the most potent naturally occurring PPAR γ agonist identified.
- The degree of PPAR γ activation dictates distinct and opposing biological responses in breast cancer cells, ranging from increased proliferation to differentiation and apoptosis.
- 15deoxy $\Delta^{12,14}$ PGJ₂ induced apoptosis requires *de novo* expression of critical gene products.
- Dominant negative expression of PPAR γ completely abrogates transcriptional activation induced by 15deoxy $\Delta^{12,14}$ PGJ₂, but does not rescue breast cancer cells from 15deoxy $\Delta^{12,14}$ PGJ₂-induced apoptosis.
- The mechanism of action of 15deoxy $\Delta^{12,14}$ PGJ₂ is not limited to PPAR γ activation. 15deoxy $\Delta^{12,14}$ PGJ₂ can inhibit isopeptidase activity of the ubiquitin proteasome and inhibit NF κ B signaling and can stimulate reactive oxygen species generation. Together, these events lead to induced expression of key gene products that are involved in apoptosis in breast cancer cells.
- 15deoxy $\Delta^{12,14}$ PGJ₂ is metabolized to polar derivatives by breast cancer cells.

Reportable Outcomes

• Manuscripts

1. **Clay CE**, Namen AM, Fonteh AN, Atsumi G, High KP, Chilton FH, 2000, 15deoxy $\Delta^{12,14}$ PGJ₂ induces diverse biological responses via PPAR γ activation in cancer cells. *Prostaglandins and Other Lipid Mediators* 62:23-32
2. **Clay CE**, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, Chilton FH, 2001, The magnitude of PPAR γ activation is associated with important and seemingly opposite biological responses in breast cancer cells. *Journal of Investigative Medicine* 49, 413-420
3. **Clay CE**, Atsumi G, High KP, Chilton FH. (2001) Early *de novo* gene expression is required for 15-Deoxy- $\Delta^{12,14}$ prostaglandin J₂ induced apoptosis in breast cancer cells. *The Journal of Biological Chemistry* 276, 47131-47135
4. Monjazebe A, **Clay CE**, High KP, Chilton FH (2001) Inhibition of arachidonic acid metabolism and remodeling blocks cancer cell proliferation; involvement of PPAR γ . *Prostaglandins and Other Lipid Mediators* 66, 5-12.
5. **Clay CE**, Thorburn J, High KP, Chilton FH. (2002) 15-Deoxy- $\Delta^{12,14}$ prostaglandin J₂-induced apoptosis does not require PPAR γ in breast cancer cells. *The Journal of Lipid Research* (In press).
6. Zhou W, **Clay CE**, High KP, Chilton FH, Robbins MC. (2002) Cyclopentenone prostaglandins induce apoptosis via oxidative stress in breast cancer cells; Role of lipid and protein oxidation. (in preparation).
7. Rogers LJ, **Clay CE**, High KP, O'Flaherty J. (2002) 5-oxo-EET is a natural PPAR γ ligand and blocks proliferation of breast and prostate cancer cells. (In preparation)

Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH. (1999) Influence of J Series Prostaglandins on Apoptosis and Tumorigenesis of Breast Cancer Cells. *Carcinogenesis* 20:1905-1911 (published prior to DOD funding).

• Abstracts

1. *PPAR γ induced apoptosis requires de novo gene expression that is suppressed by a dominant negative mutant in breast cancer cells.* FASEB: Receptors and Signal Transduction, Copper Mountain, CO July 2-9, 2000
2. *15deoxy $\Delta^{12,14}$ PGJ₂ inhibits breast cancer cell proliferation via PPAR γ activation.* International Society for Preventive Oncology, 5th International Meeting, Geneva, Switzerland, October 28-31, 2000, Satellite Symposium October 29, 2000

3. *PPAR γ induced apoptosis requires de novo gene expression that is suppressed by a dominant negative mutant in breast cancer cells.* Wake Forest University, Breast Cancer Center of Excellence, Winston Salem, NC, November 16, 2000
4. *PPAR γ induced apoptosis requires de novo gene expression that is suppressed by a dominant negative mutant in breast cancer cells.* Keystone Symposium: PPARs a transcription odyssey, Keystone, CO, February 2-9, 2001
5. *Mechanisms of 15deoxy $\Delta^{12,14}$ PGJ₂ induced apoptosis in breast cancer cells.* Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Nashville, TN October 14-17, 2001
6. *PPAR γ does not mediate apoptosis in breast cancer cells: role for lipid and protein modification.* South Eastern Regional Lipid Conference, Cashiers, NC, November 7-9, 2001

• Presentations

1. *PPAR γ induced biologic responses require de novo gene expression that is suppressed by a dominant negative mutant in breast cancer cells.* Wake Forest University Cancer Center Faculty Retreat, Winston-Salem, NC, August 11-12, 2000
2. *15deoxy $\Delta^{12,14}$ PGJ₂ induced apoptosis is suppressed by a PPAR γ dominant negative.* South Eastern Regional Lipid Conference, Cashiers, NC, November 1-3, 2000
3. *Mechanisms of Apoptosis in breast cancer cells: 15deoxy $\Delta^{12,14}$ PGJ₂ and PPAR γ .* University of Colorado Health Sciences Center, Denver, CO, February 9, 2001.
4. *PPAR γ does not mediate apoptosis in breast cancer cells: role for lipid and protein modification.* South Eastern Regional Lipid Conference, Cashiers, NC, November 7-9, 2001

• Awards

1. Comprehensive Cancer Center Award: Best graduate student presentation (monetary award) *PPAR γ induced biologic changes require de novo gene expression that is suppressed by a dominant negative mutant in breast cancer cells.* Wake Forest University Cancer Center Faculty Retreat, August 11-12, 2000
2. Avanti Founder's Award: Best graduate student presentation (monetary award and conference expenses) *15deoxy $\Delta^{12,14}$ PGJ₂ induced apoptosis is suppressed by a PPAR γ dominant negative.* South Eastern Regional Lipid Conference, Cashiers, NC, November 1-3, 2000
3. Avanti Founder's Award: Outstanding graduate student presentation (monetary award and conference expenses) *15deoxy $\Delta^{12,14}$ PGJ₂ induced apoptosis is suppressed by a PPAR γ dominant negative.* South Eastern Regional Lipid Conference, Cashiers, NC, November 1-3, 2000
4. Cayman Chemical Travel Award (monetary award) *Mechanisms of 15deoxy $\Delta^{12,14}$ PGJ₂ induced apoptosis in breast cancer cells.* Eicosanoids and Other Bioactive Lipids in Cancer, Inflammation and Related Diseases, Nashville, TN October 14-17, 2001
5. Avanti Founder's Award: Outstanding graduate student presentation (monetary award and conference expenses) *PPAR γ does not mediate apoptosis in breast cancer cells: role for lipid and protein modification.* South Eastern Regional Lipid Conference, Cashiers, NC, November 7-9, 2001

• Funding applied for based on work supported by this award

1. Susan G. Komen Breast Cancer Foundation Dissertation Award. *PPAR γ Induced Apoptosis Requires de novo Gene Expression in Breast Cancer Cells: searching for key molecular targets.* (submitted March 15, 2001)

2. Wake Forest University Comprehensive Cancer Center. *PPAR γ and soy phytoestrogens as possible therapy for breast cancer*. \$10,000 (submitted March 15, 2001)
3. Wake Forest University Comprehensive Cancer Center. *Adaptation of Cancer Cells to Oxidative Stress and the Anti-Cancer Mechanism of 15-deoxy-prostaglandin J₂*. \$25,000 (submitted November 16, 2001, not funded)

Conclusions

Naturally occurring derivatives of arachidonic acid metabolism are potent and effective activators of PPAR γ . The most potent of these derivatives is 15deoxy $\Delta^{12,14}$ PGJ₂ (15dPGJ₂), the dehydration and isomerization product of prostaglandin D₂ (PGD₂). 15dPGJ₂ induces PPAR γ mediated transcriptional activation leading to the synthesis of critical gene products involved in cell cycle arrest and apoptosis. Of these gene products, expression of the cyclin dependent kinase inhibitors, p21 and p27, is associated with marked cell cycle arrest with subsequent apoptosis involving caspase-3. Although 15dPGJ₂ inhibits NF κ B mediated transcription, this likely represents a minor contribution to 15dPGJ₂ induced apoptosis in breast cancer cells. Other candidate mechanisms include inhibition of the ubiquitin proteasome and generation of novel oxidized lipid intermediates. Investigations into altered fatty acid metabolism pathways are underway and may yield clues as to how arachidonic acid derivative exert such potent anti-neoplastic activity in breast cancer cells. 15dPGJ₂ may represent a novel class of therapeutic molecules for the treatment of breast cancer.

References

1. **Clay CE**, Namen AM, Fonteh AN, Atsumi G, High KP, Chilton FH. (2000) 15deoxy $\Delta^{12,14}$ PGJ₂ induces diverse biological responses via PPAR γ activation in cancer cells. *Prostaglandins and Other Lipid Mediators* 62:23-32
2. **Clay CE**, Namen AM, Atsumi G, Trimboli AJ, Fonteh AN, High KP, Chilton FH. (2001) The magnitude of PPAR γ activation is associated with important and seemingly opposite biological responses in breast cancer cells. *Journal of Investigative Medicine* 49, 413-420
3. **Clay CE**, Atsumi G, High KP, Chilton FH. (2001) Early *de novo* gene expression is required for 15-Deoxy- $\Delta^{12,14}$ prostaglandin J₂ induced apoptosis in breast cancer cells. *The Journal of Biological Chemistry* 276, 47131-47135
4. Monjazebe A, **Clay CE**, High KP, Chilton FH (2001) Inhibition of arachidonic acid metabolism and remodeling blocks cancer cell proliferation; involvement of PPAR γ . *Prostaglandins and Other Lipid Mediators* 66, 5-12.
5. **Clay CE**, Thorburn J, High KP, Chilton FH. (2002) 15-Deoxy- $\Delta^{12,14}$ prostaglandin J₂-induced apoptosis does not require PPAR γ breast cancer cells. *The Journal of Lipid Research* (In press).
6. Zhou W, **Clay CE**, High KP, Chilton FH, Robbins MC. (2002) Cyclopentenone prostaglandins induce apoptosis via oxidative stress in breast cancer cells; Role of lipid and protein oxidation. (in preparation).
7. Rogers LJ, **Clay CE**, High KP, O'Flaherty J. (2002) 5-oxo-EET is a natural PPAR γ ligand and blocks proliferation of breast and prostate cancer cells. (In preparation)

Clay CE, Namen AM, Atsumi G, Willingham MC, High KP, Kute TE, Trimboli AJ, Fonteh AN, Dawson PA, Chilton FH. (1999) Influence of J Series Prostaglandins on Apoptosis and Tumorigenesis of Breast Cancer Cells. *Carcinogenesis* 20:1905-1911 (published prior to DOD funding).

Appendices

Appendix 1: **Mechanisms of 15deoxy $\Delta^{12,14}$ PGJ₂ induces apoptosis in breast cancer cells.** 15dPGJ₂ induced apoptosis in breast cancer cells requires the expression of critical gene products, such as p21 and p27. However, 15dPGJ₂ also induces the generation of reactive oxygen species which may act on free arachidonic acid (AA) to yield novel nuclear receptor agonists. Moreover, 15dPGJ₂ inhibits key survival signaling protein, such as NF κ B and AKT/PKB, and inhibits isopeptidase activity of the ubiquitin proteasome. Together these data show that the extraordinary biological activity of 15dPGJ₂ is a result of PPAR γ -dependent and independent mechanisms. Further research is warranted to discern the predominant mechanisms of 15dPGJ₂-induced apoptosis in breast cancer cells.

